Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS

1 September 2020 - Detects, confirms and differentiates HIV-1 and HIV-2 infections providing clinicians with critical diagnostic data for personalised management ...

Read more →

China National Medical Products Administration approves Truvada for HIV pre-exposure prophylaxis

11 August 2020 - Truvada is the first HIV PrEP medicine approved in China. ...

Read more →

Access to HIV medicines severely impacted by COVID-19 as AIDS response stalls

6 July 2020 - Countries seek innovative ways to mitigate the impact of disruptions and keep services going. ...

Read more →

Gilead Canada submits supplemental new drug submission to Health Canada for Descovy for HIV pre-exposure prophylaxis

9 April 2020 - Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy compared ...

Read more →

HIV drug PrEP to be available across England

15 March 2020 - PrEP will be routinely available across England as part of the government’s aim to end HIV transmission ...

Read more →

PrEP school: a field manual for the battle over HIV prevention drug pricing

29 August 2019 - Pre-exposure prophylaxis (PrEP)—an HIV prevention intervention consisting of a daily drug cocktail, quarterly HIV/sexually transmitted disease screening, ...

Read more →

Gilead files challenge to government patents for HIV prevention pill

21 August 2019 - Gilead Sciences took the unusual step of mounting a challenge to U.S. government patents on Wednesday, ...

Read more →

China National Medical Products Administration approves Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) for treatment of HIV-1 infection

9 August 2019 - Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks. ...

Read more →

Patient groups push back against Gilead's pricey HIV prevention treatment

7 August 2019 - Gilead Sciences hopes to soon introduce a pricey new pill to prevent HIV in people at risk ...

Read more →

How Australia could almost eradicate H.I.V. transmissions

10 July 2019 - It took universal health care, political will and a health campaign designed to terrify the public, ...

Read more →

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

9 July 2019 - The long-acting injectable regimen has been granted priority review status by the FDA, with a target approval ...

Read more →

ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

3 July 2019 - Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug ...

Read more →

HIV diagnoses in Australia hit 18-year low, but there is still a way go

3 July 2019 - Australia has solidified its reputation as a world leader in HIV prevention, recording its lowest number ...

Read more →

FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV

1 July 2019 - The U.S. FDA approved Truvada (emtricitabine/tenofovir disoproxil fumarate) in 2004 for the treatment of HIV-1 infection in ...

Read more →

A million Americans need this drug. Trump’s deal won’t help enough of them.

13 May 2019 - A donation of HIV prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients. ...

Read more →